NR4A1 and breast carcinoma: Nowadays, despite the well-known molecular heterogeneity of breast cancer and the identification of important mutations that characterize different subtypes, the only clinically relevant biomarkers and validated therapeutic targets are the hormone receptors ER, PR, and HER2.